



IN8bio to Present at April Investor and Scientific Conferences

April 5, 2022

NEW YORK, April 05, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, today announced April conference presentations:

- **American Association for Cancer Research (AACR) Annual Meeting 2022 (New Orleans), April 8 – 13, 2022**
 - Lawrence Lamb, Ph.D., CSO, will present “Maintenance-Phase Temozolomide as a Lymphodepletion Platform for Intracranial Adoptive $\gamma\delta$ T Cell-Based Therapy in Primary High-Grade Gliomas”
 - April 11, 2022, 9:00 – 12:30 p.m. CDT
 - Visit <https://bit.ly/3JRDUum>

 - Lei Ding, Ph.D., Lead Program Scientist, will present “Dual Chlorotoxin and Methylguanine-DNA Methyltransferase (MGMT) $\gamma\delta$ T Cells for Drug Resistant Immunotherapy”
 - April 13, 2022, 9:00 – 12:30 p.m. CDT
 - Visit <https://bit.ly/3JQF1KV>

- **BIO Alabama Annual Conference 2022 (Birmingham) April 25 – 26, 2022**
 - William Ho, CEO, will be on a panel highlighting successful Alabama biotechnology companies.
 - April 25, 2022
 - Visit <https://bit.ly/3DtKW6h>

About IN8bio

IN8bio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell product candidates for solid and liquid tumors. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. IN8bio's DeltEx platform employs allogeneic, autologous and genetically modified approaches to develop cell therapies, designed to effectively identify and eradicate tumor cells.

IN8bio is currently conducting two investigator-initiated Phase 1 clinical trials for its lead gamma-delta T cell product candidates: INB-200 for the treatment of newly diagnosed glioblastoma and INB-100 for the treatment of patients with leukemia undergoing hematopoietic stem cell transplantation. IN8bio also has a broad portfolio of preclinical programs focused on addressing other solid tumor types. For more information about IN8bio and its programs, please visit www.IN8bio.com.

Contacts

IN8bio, Inc.
Kate Rochlin, Ph.D.
+1 646.600.6438
kmrochlin@in8bio.com

Investors:

Solebury Trout
David Buck
+1 646.378.2927
dbuck@soleburytrout.com

Media:

Burns McClellan, Inc.
Katie Larch / Robert Flamm, Ph.D.
klarch@burnsmc.com / rflamm@burnsmc.com